Commercial Expertise: We provide expert advice on the commercialisation of biotech and MedTech innovations, beyond the Regulatory Clearances, i.e. Health Economics, Reimbursement, Distribution and most importantly Adoption. Med2Mark thoroughly assesses the commercial
value of Health-Tech innovations before significant investments are committed. We are selective and engage, for the long run, in projects with strong commercialisation and actual adoption potentials.
Global Experience: We are an international boutique Consulting Practice. Our Advisors come from 7 different countries and are spread over 3 continents. Cumulatively, we have Over 100 years of direct "hands-on" experience in the
commercialisation of Biotech and Medtech innovations in the USA, Europe and Australia.
Med2Mark offers an "Executive" engagement model where we embed ourselves in the client organisation at Executive or Board levels, as illustrated by David’s, Attilio’s as well as Pierre’s Executive positions in startups we came across through
our consulting activities.
Definition of Health Impact Strategies: Assessment of the heathcare system’s capacity to maximise the potential benefits of your innovation at the delivery point.
Substantiation of Health Economics value to build Reimbursement dossiers: Clinical and economic...
Market Access Strategy: We map out the regulatory pathways and reimbursement options applicable to your innovation.
Markets Assessment & Financial Modelling: From the Global Market to the Total Addressable Market, we provide you with actionable information...
KOLs Engagement & early adoption: Engagement of subject experts and Key Opinion Leaders to accelerate early adoption of your innovation.
Validate the financial projections to support fundraising activities and exit negotiations.
Advice to Investors based on expected commercial returns: We translate the complexities of healthtech commercialisation into a succinct dashboard...